Nice little bit of help:
JERSEY CITY, N.J., March 8 /PRNewswire/ -- The following is being issued by M.H. Meyerson & Co., Inc., a member of the National Association of Securities Dealers, CRD number 540:
M.H. Meyerson & Co., Inc. (Nasdaq: MHMY) has raised its price target on Genome Therapeutics Corporation (Nasdaq: GENE) to $85 to reflect strong market demand. Further, we are maintaining our original earnings estimates of ($0.15) per share, or a net loss of $2.9 million, which corrects our previous report, for the fiscal year ending August 2000, and ($0.02) per share in the fiscal year ending August 2001. For more information contact Andrew H. Scott, Director of Research, or Jeffrey H. Berg, Ph.D., at 201-459-9440 or 800-422-4114; web site: mhmeyerson.com. |
